ALSO NOTED: Bayer drug moves up to first-line leukemia treatment; St. Jude Medical adding 1,200 jobs in Puerto Rico

> Bayer got the FDA's blessing to market its Campath leukemia drug as a first-line treatment against the disease; previously, Campath was only approved for use when other therapies had failed. Made by Genzyme, the drug is marketed by Bayer under license in the U.S. Release

> Device maker St. Jude Medical says it will add 1,200 new jobs in Arecibo, Puerto Rico as it ramps up production at a newly purchased plant there. Report

> Cardinal Health and Alliance Boots are joining forces to launch the generic brand Almus in the U.S. Report

> Indian drug maker Ranbaxy Laboratories says it will appeal a Canadian court's decision to block its launch of a generic form of Lipitor, Pfizer's blockbuster cholesterol drug. Report

> Novo Nordisk got E.U. approval to use its NovoRapid insulin product in the elderly. Report

> According to new trial data, Merck's Gardasil vaccine against the virus that causes cervical cancer also cross-protects against 10 strains not directly targeted by the shot--making it useful in developing countries where those 10 strains are most prevalent. Report

> Celera Group agreed to buy Atria Genetics, a maker of bone marrow testing products, for $33 million. Report

And Finally... Forget diet and exercise--there's a shot that'll zap fat away. Trouble is, it's not FDA-approved, it's not standardized and it could be dangerous. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.